Literature DB >> 7694663

Lymphoid subsets in acute myeloid leukemias: increased number of cells with NK phenotype and normal T-cell distribution.

M B Vidriales1, A Orfao, M C López-Berges, M González, J M Hernandez, J Ciudad, A López, M J Moro, M Martínez, J F San Miguel.   

Abstract

Natural killer (NK) and T subsets were analyzed with appropriate dual labeling by flow cytometry in peripheral blood (PB) (66 cases) and bone marrow (BM) (55 cases) from patients with de novo AML in order to determine: (a) their distribution at diagnosis, (b) the correlation between PB and BM in NK subpopulations, (c) their relationship with the clinical and hematological disease characteristics, and (d) the changes occurring upon achieving complete remission (CR). NK cells defined by the expression of CD56 in the absence of CD3 were significantly increased at diagnosis and their levels in PB correlated with those of BM. By contrast, NK subsets defined by CD16 expression (CD16+ CD2+ and CD16+ CD2- NK-cell subsets) as well as T lymphocytes with NK activity (CD56+ CD3+), although increased in PB, displayed normal levels in BM. An additional observation of interest was the expansion of an immature NK population lacking CD16 Ag expression (CD56+ CD16-). AML cases were divided into two groups according to the absolute number of NK cells in PB; patients with the highest levels showed an increased proportion of blast cells in PB (p = 0.01), monocytic subtypes (p = 0.03), and expression of CD11b, CD14, and CD4 antigens (p = 0.05). Infections at diagnosis were not related to the level of NK cells. In 19 patients who achieved complete remission the number of CD56+ CD3- cells tended to be reduced to within the normal range. Other T-cell populations, including the CD4 naive and memory cells, were also explored, their distribution being normal in the PB of AML patients. By contrast, the cytotoxic subset CD8+/CD57+ was significantly increased (p < 0.001). These data point to the existence of marked alterations of NK cells in AML patients, possibly reflecting a host-tumor immunological interaction.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7694663     DOI: 10.1007/bf01715050

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  36 in total

Review 1.  Biology and clinical relevance of human natural killer cells.

Authors:  M J Robertson; J Ritz
Journal:  Blood       Date:  1990-12-15       Impact factor: 22.113

2.  Production of tumour-derived suppressor factor in patients with acute myeloid leukaemia.

Authors:  S H Lim; C P Worman; A Jewell; A H Goldstone
Journal:  Leuk Res       Date:  1991       Impact factor: 3.156

3.  The use of interleukin-2 and lymphokine-activated killer cells for the treatment of patients with non-Hodgkin's lymphoma.

Authors:  J S Weber; J C Yang; S L Topalian; D J Schwartzentruber; D E White; S A Rosenberg
Journal:  J Clin Oncol       Date:  1992-01       Impact factor: 44.544

4.  Natural killer cell-mediated inhibition of growth of myeloid and lymphoid clonogenic leukemias.

Authors:  C A Savary; E Lotzová
Journal:  Exp Hematol       Date:  1989-02       Impact factor: 3.084

5.  Cytotoxicity of purified Leu 19+ cells from the peripheral blood of children with acute lymphocytic leukemia.

Authors:  Z A Afify; A Abdel-Mageed; H W Findley; A H Ragab
Journal:  Cancer       Date:  1990-08-01       Impact factor: 6.860

6.  Resistance of leukemic blasts to lymphokine activated killer (LAK)-mediated cytotoxicity is not related to their adhesion properties.

Authors:  A K Palucka; A Porwit; P Reizenstein
Journal:  Eur J Haematol       Date:  1991-08       Impact factor: 2.997

7.  Loss of natural killer activity as an indicator of relapse in acute leukaemia.

Authors:  J A Tratkiewicz; J Szer
Journal:  Clin Exp Immunol       Date:  1990-05       Impact factor: 4.330

8.  Acute leukemia after a primary myelodysplastic syndrome: immunophenotypic, genotypic, and clinical characteristics.

Authors:  J F San Miguel; J M Hernández; R González-Sarmiento; M González; I Sánchez; A Orfao; M C Cañizo; A López Borrasca
Journal:  Blood       Date:  1991-08-01       Impact factor: 22.113

9.  Defective lymphokine-activated killer cell generation and activity in acute leukemia patients with active disease.

Authors:  R Foa; M T Fierro; A Cesano; A Guarini; M Bonferroni; D Raspadori; R Miniero; F Lauria; F Gavosto
Journal:  Blood       Date:  1991-08-15       Impact factor: 22.113

10.  T-cell subpopulations in patients with monoclonal gammopathies: essential monoclonal gammopathy, multiple myeloma, and Waldenstrom macroglobulinemia.

Authors:  J F San Miguel; M D Caballero; M Gonzalez
Journal:  Am J Hematol       Date:  1985-11       Impact factor: 10.047

View more
  15 in total

Review 1.  CD8+ CD28- and CD8+ CD57+ T cells and their role in health and disease.

Authors:  Marius Strioga; Vita Pasukoniene; Dainius Characiejus
Journal:  Immunology       Date:  2011-06-29       Impact factor: 7.397

Review 2.  Immune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilled.

Authors:  Jan Philipp Bewersdorf; Maximilian Stahl; Amer M Zeidan
Journal:  Expert Rev Anticancer Ther       Date:  2019-03-19       Impact factor: 4.512

3.  Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study.

Authors:  Farhad Ravandi; Rita Assi; Naval Daver; Christopher B Benton; Tapan Kadia; Philip A Thompson; Gautam Borthakur; Yesid Alvarado; Elias J Jabbour; Marina Konopleva; Koichi Takahashi; Steven Kornblau; Courtney D DiNardo; Zeev Estrov; Wilmer Flores; Sreyashi Basu; James Allison; Padmanee Sharma; Sherry Pierce; Allison Pike; Jorge E Cortes; Guillermo Garcia-Manero; Hagop M Kantarjian
Journal:  Lancet Haematol       Date:  2019-08-07       Impact factor: 18.959

4.  Bone marrow T-cell percentage: A novel prognostic indicator in acute myeloid leukemia.

Authors:  Manar M Ismail; Nahla A B Abdulateef
Journal:  Int J Hematol       Date:  2016-12-01       Impact factor: 2.490

Review 5.  Microenvironmental Features Driving Immune Evasion in Myelodysplastic Syndromes and Acute Myeloid Leukemia.

Authors:  Georgios Petros Barakos; Eleftheria Hatzimichael
Journal:  Diseases       Date:  2022-06-10

6.  Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts.

Authors:  Rifca Le Dieu; David C Taussig; Alan G Ramsay; Richard Mitter; Faridah Miraki-Moud; Rewas Fatah; Abigail M Lee; T Andrew Lister; John G Gribben
Journal:  Blood       Date:  2009-08-26       Impact factor: 22.113

7.  Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia.

Authors:  Helena Ågerstam; Christine Karlsson; Nils Hansen; Carl Sandén; Maria Askmyr; Sofia von Palffy; Carl Högberg; Marianne Rissler; Mark Wunderlich; Gunnar Juliusson; Johan Richter; Kjell Sjöström; Ravi Bhatia; James C Mulloy; Marcus Järås; Thoas Fioretos
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-10       Impact factor: 11.205

Review 8.  The emerging role of immune checkpoint based approaches in AML and MDS.

Authors:  Prajwal Boddu; Hagop Kantarjian; Guillermo Garcia-Manero; James Allison; Padmanee Sharma; Naval Daver
Journal:  Leuk Lymphoma       Date:  2017-07-06

Review 9.  Bone marrow micro-environment is a crucial player for myelomagenesis and disease progression.

Authors:  Patrizia Mondello; Salvatore Cuzzocrea; Michele Navarra; Michael Mian
Journal:  Oncotarget       Date:  2017-03-21

Review 10.  Therapeutic Antibodies for Myeloid Neoplasms-Current Developments and Future Directions.

Authors:  Christian M Schürch
Journal:  Front Oncol       Date:  2018-05-18       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.